## Melittin-encapsulating Peptide Hydrogels for Enhanced Delivery of Impermeable Anticancer Peptides

*Jue-Ping Feng*,  $^{1*^{\dagger}}$  *Ru Zhu*,  $^{1^{\dagger}}$  *Fagang Jiang*,  $^{^{t}}$  *Jie Xie*,  $^{\dagger}$  *Chang Gao*,  $^{\dagger}$  *Min Li*,  $^{\dagger}$  *Honglin Jin*  $^{^{s}}$  *and Dehao Fu*<sup>&</sup>\*

<sup>†</sup>Department of Oncology, Wuhan Fourth Hospital; PuAi Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430034, China. <sup>‡</sup> Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

<sup>§</sup> Department of Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

<sup>&</sup>Department of Orthopaedics, West Campus, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan Hubei, 430056, P.R. China

<sup>1</sup>These authors contributed equally to this work.

\*Correspondence: Department of Oncology, Wuhan Fourth Hospital; Wuhan PuAi Hospital, Tongji Medical College, Huazhong University of Science and Technology, 76 Jiefang Avenue, Wuhan, 430034, China.

Email: Dehao Fu, fudehao@hust.edu.cn; Jue-Ping Feng, fengjuepingpuai@163.com

**KEYWORDS.** cancer therapy, anticancer peptides, Melittin, controlled drug release, cell membrane permeability

## **Experimental Section**

Materials and cell lines. KLA (KLAKLAKKLAKLAK)<sub>D</sub>, Melittin (GIGAVLKVLTTGLPALISWIKRKRQQ), and RADA<sub>28</sub>-melittin fusion peptide (Ac-RADARADARADARADA-GG-GIGAVLKVLTTGLPALISWIKRKRQQ-NH2) were synthesized by Bankpeptide Ltd. (Hefei, China).

CT-26 cells were purchased from the Chinese Type Culture Collection (CTCC) and were maintained in RPMI 1640 medium (Gibico) with 10% FBS (Gibico) and 100 ug/mL antibiotics (penicillin and streptomycin) in an atmosphere of 5% CO<sub>2</sub> at 37 °C.

**Preparation of MRP hydrogel.** The KLA solution (10 mM) was obtained by dissolving 5 mg of KLA powder in ultrapure water at room temperature. To prepare MR hydrogel, 10 mg MR peptides were dissolved in 1 mL 0.9% NaCl solution and kept at 4 °C overnight. In the same way, 10 mg MR peptides and different dosages of KLA peptide were dissolved in 1 mL 0.9% NaCl solution and kept at 4 °C overnight to prepare MRP hydrogel. All procedures were performed under sterile conditions.

Cell viability assay. CT26 cells (5000 cells/well) were seeded in 96-well plates with 100  $\mu$ L of culture medium and cultured at 37 °C and 5% CO<sub>2</sub> overnight. Then various concentrations of MR (concentration: 0-15 mg/mL) were added in quadruplicates to the culture media. After incubation for 24 at 37 °C, the cell viability was determined using the CCK8 assay (Beyotime).

Statistical Analysis. Data in this study are presented as mean  $\pm$  standard error of the mean (SEM). For *in vitro* studies, unpaired Student t-tests were used for statistical comparison. Tumor growth was analyzed using the Kaplan-Meier method. Statistical significance was expressed as \* for p < 0.05, \*\* for p < 0.01, and \*\*\* for p < 0.001.



Supporting Figure 1. Procedure of gelation under physiological conditions.



**Supporting Figure 2.** Cell viability measurement using the CCK-8 assay after treatment with MR hydrogel for 24 h. Data are presented as the mean  $\pm$  SEM (n = 4).